✦ LIBER ✦

WS6.5 Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation

✍ Scribed by J.C. Davies; H. Li; K. Yen; R. Ahrens

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

WS6.4 Long-term safety and efficacy of i

✍ E. McKone; H. Li; K. Yen; J.C. Davies 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Efficacy and Safety of Ivacaftor in Pati

✍ Davies, Jane C.; Wainwright, Claire E.; Canny, Gerard J.; Chilvers, Mark A.; How 📂 Article 📅 2013 🏛 American Thoracic Society 🌐 English ⚖ 646 KB

WS6.3 Measures of nutritional status in

✍ D. Borowitz; B. Ramsey; Q. Dong; K. Yen; J.S. Elborn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

46 Hyperpolarized Gas MRI of ivacaftor t

✍ T. Altes; M.A. Johnson; G.W. Miller; J.P. Mugler; L. Flors; J. Mata; C.L. Salina 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

WS1.1 The effect of ivacaftor, a CFTR po

✍ De Boeck, K.; Munck, A.; Walker, S.; Faro, A.; Hiatt, P.; Chan, J.; Gilmartin, G 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 70 KB

44 Pulmonary exacerbations in a Phase 3

✍ M. Griese; B. Ramsey; S. Rodriguez; K. Yen; J.S. Elborn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB